Faculty Opinions recommendation of Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
2003 ◽
Vol 1
(5)
◽
pp. S167
◽
2005 ◽
Vol 23
(16_suppl)
◽
pp. 3209-3209
◽
2004 ◽
Vol 10
(15)
◽
pp. 5027-5037
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 3018-3018
◽